Warning: Warning regarding Remexian products following a product authorisation review by a wholesaler: As part of a product authorisation review conducted by a wholesaler, it was noted that Remexian had placed different cannabis flower products on the market under the same authorisation number, even though they were based on different cultivars (for example, several Madrecan variants with differing strains). With reference to the German Medicinal Products Act (§ 7 AMG) and the relevant guidance issued by the BfArM, it was explained that a separate authorisation would have been required for each combination of cultivar and active ingredient content. Using one authorisation number for multiple different cultivars was therefore not considered compliant and could potentially have regulatory as well as competition-law relevance. Against this background, it was decided not to continue distributing Remexian products in order to ensure a legally secure and reliable supply.